RU2012144392A - Композиции липидных везикул и способы применения - Google Patents
Композиции липидных везикул и способы применения Download PDFInfo
- Publication number
- RU2012144392A RU2012144392A RU2012144392/15A RU2012144392A RU2012144392A RU 2012144392 A RU2012144392 A RU 2012144392A RU 2012144392/15 A RU2012144392/15 A RU 2012144392/15A RU 2012144392 A RU2012144392 A RU 2012144392A RU 2012144392 A RU2012144392 A RU 2012144392A
- Authority
- RU
- Russia
- Prior art keywords
- lipid
- vesicle
- multilayer
- functionalized
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Многослойная липидная везикула, имеющая сшивки между липидными бислоями.2. Многослойная липидная везикула по п.1, причем везикула содержит функционализированный липид.3. Многослойная липидная везикула по п.1 или 2, причем везикула содержит фосфохолин.4. Многослойная липидная везикула по п.1 или 2, причем везикула содержит глицерофосфат.5. Многослойная липидная везикула по п.2, в которой функционализированным липидом является малеимид-функционализированный липид.6. Многослойная липидная везикула по п.1, причем везикула содержит средство.7. Многослойная липидная везикула по п.6, в которой средством является профилактическое средство, терапевтическое средство или диагностическое средство.8. Многослойная липидная везикула по п.6, в которой средством является антиген.9. Многослойная липидная везикула по п.6, в которой средством является адъювант.10. Многослойная липидная везикула по п.6, в которой средством является белок.11. Многослойная липидная везикула по п.6, причем средство инкапсулировано в везикулу.12. Многослойная липидная везикула по п.6 или 11, в которой средство инкапсулировано между липидными бислоями.13. Многослойная липидная везикула по п.1 или 2, причем везикула конъюгирована с полиэтиленгликолем (PEG).14. Многослойная липидная везикула по п.1 или 2, причем везикула содержит DOPC, DOPG и малеимид-функционализированный липид.15. Многослойная липидная везикула по п.14, в которой малеимид-функционализированным липидом является малеимид-функционализированный фосфоэтаноламин.16. Композиция, содержащая многослойную липидную везикулу по любому из пп.1-15 и фармацевтически приемлемый носитель.17. Композиция, содержащая многосл�
Claims (52)
1. Многослойная липидная везикула, имеющая сшивки между липидными бислоями.
2. Многослойная липидная везикула по п.1, причем везикула содержит функционализированный липид.
3. Многослойная липидная везикула по п.1 или 2, причем везикула содержит фосфохолин.
4. Многослойная липидная везикула по п.1 или 2, причем везикула содержит глицерофосфат.
5. Многослойная липидная везикула по п.2, в которой функционализированным липидом является малеимид-функционализированный липид.
6. Многослойная липидная везикула по п.1, причем везикула содержит средство.
7. Многослойная липидная везикула по п.6, в которой средством является профилактическое средство, терапевтическое средство или диагностическое средство.
8. Многослойная липидная везикула по п.6, в которой средством является антиген.
9. Многослойная липидная везикула по п.6, в которой средством является адъювант.
10. Многослойная липидная везикула по п.6, в которой средством является белок.
11. Многослойная липидная везикула по п.6, причем средство инкапсулировано в везикулу.
12. Многослойная липидная везикула по п.6 или 11, в которой средство инкапсулировано между липидными бислоями.
13. Многослойная липидная везикула по п.1 или 2, причем везикула конъюгирована с полиэтиленгликолем (PEG).
14. Многослойная липидная везикула по п.1 или 2, причем везикула содержит DOPC, DOPG и малеимид-функционализированный липид.
15. Многослойная липидная везикула по п.14, в которой малеимид-функционализированным липидом является малеимид-функционализированный фосфоэтаноламин.
16. Композиция, содержащая многослойную липидную везикулу по любому из пп.1-15 и фармацевтически приемлемый носитель.
17. Композиция, содержащая многослойную липидную везикулу по любому из пп.1-15 и вспомогательное вещество, приемлемое для лиофилизации.
18. Композиция, содержащая многослойную липидную везикулу по п.17, в которой вспомогательное вещество, приемлемое для лиофилизации, содержит сахарозу.
19. Способ, включающий
контактирование липосом, содержащих функционализированный липид, с двухвалентным катионом с образованием слитых липосом и
контактирование слитых липосом со сшивателем с образованием многослойных липидных везикул, имеющих сшивки между липидными бислоями.
20. Способ по п.19, в котором функционализированным липидом является малеимид-функционализированный липид.
21. Способ по п.19 или 20, в котором липосомы содержат фосфохолин.
22. Способ по п.19 или 20, в котором липосомы содержат глицерофосфат.
23. Способ по п.19, в котором липосомы содержат малеимид-функционализированный липид, фосфохолин и глицерофосфат.
24. Способ по п.19 или 20, в котором функционализированным липидом является функционализированный фосфоэтаноламин.
25. Способ по п.23, в котором малеимид-функционализированным липидом является малеимид-функционализированный фосфоэтаноламин.
26. Способ по п.19 или 20, в котором сшивателем является дитиоловый сшиватель.
27. Способ по п.19 или 20, в котором сшивателем является дитиотреитол (DTT).
28. Способ по п.19 или 20, дополнительно включающий конъюгирование полиэтиленгликоля (PEG) с поверхностью многослойных липидных везикул, имеющих сшивки между липидными бислоями.
29. Способ по п.19 или 20, в котором двухвалентными катионами являются Са2+.
30. Способ по п.19 или 20, в котором двухвалентными катионами являются Mg2+.
31. Способ по п.19 или 20, в котором контактирование происходит в водном буфере.
32. Способ по п.19 или 20, в котором липосомы содержат средство.
33. Способ по п.32, в котором средством является профилактическое средство, терапевтическое средство или диагностическое средство.
34. Способ по п.19 или 20, в котором липосомы получены с использованием DOPC, DOPG и малеимид-функционализированного липида в мольном отношении 40:10:50.
35. Способ по п.19 или 20, в котором мольное отношение дитиолового сшивателя к малеимид-функционализированному липиду составляет 1:2.
36. Способ, включающий
контактирование многослойной липидной везикулы, содержащей функционализированный липид, со сшивателем с образованием многослойных липидных везикул, имеющих сшивки между липидными бислоями.
37. Способ, включающий
введение субъекту многослойной липидной везикулы, имеющей сшитые липидные бислои, которая содержит средство в эффективном количестве.
38. Способ по п.37, в котором многослойная липидная везикула содержит биоразлагаемый липид.
39. Способ по п.37 или 38, в котором многослойная липидная везикула содержит фосфолипид.
40. Способ по п.37 или 38, в котором многослойная липидная везикула содержит фосфохолин, глицерофосфат и/или фосфоэтаноламин.
41. Способ по п.37 или 38, в котором многослойная липидная везикула содержит функционализированный липид.
42. Способ по п.41, в котором функционализированным липидом является малеимид-функционализированный липид.
43. Способ по п.42, в котором малеимид-функционализированным липидом является малеимид-функционализированный фосфоэтаноламин.
44. Способ по п.37 или 38, в котором средством является профилактическое средство.
45. Способ по п.37 или 38, в котором средством является терапевтическое средство.
46. Способ по п.37 или 38, в котором средством является антиген.
47. Способ по п.37 или 38, в котором средством является адъювант.
48. Способ по п.37 или 38, в котором многослойная липидная везикула содержит более чем одно средство.
49. Способ по п.37 или 38, в котором многослойная липидная везикула содержит два средства.
50. Способ по п.49, в котором многослойная липидная везикула содержит антиген и адъювант.
51. Способ по п.37 или 38, в котором многослойная липидная везикула конъюгирована с PEG на своей внешней поверхности.
52. Способ, включающий
контактирование многослойной липидной везикулы, имеющей сшитые липидные бислои, которая содержит средство, с клеткой in vitro.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31548510P | 2010-03-19 | 2010-03-19 | |
| US61/315,485 | 2010-03-19 | ||
| US31970910P | 2010-03-31 | 2010-03-31 | |
| US61/319,709 | 2010-03-31 | ||
| PCT/US2011/000502 WO2011115684A2 (en) | 2010-03-19 | 2011-03-19 | Lipid vesicle compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012144392A true RU2012144392A (ru) | 2014-04-27 |
| RU2595872C2 RU2595872C2 (ru) | 2016-08-27 |
Family
ID=44202533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012144392/15A RU2595872C2 (ru) | 2010-03-19 | 2011-03-19 | Композиции липидных везикул и способы применения |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8747869B2 (ru) |
| EP (1) | EP2547327B1 (ru) |
| JP (1) | JP5686886B2 (ru) |
| KR (1) | KR101783068B1 (ru) |
| CN (1) | CN102917690B (ru) |
| AU (1) | AU2011227686B2 (ru) |
| BR (1) | BR112012023501A2 (ru) |
| CA (1) | CA2793604C (ru) |
| IL (1) | IL221989A (ru) |
| MX (1) | MX2012010810A (ru) |
| RU (1) | RU2595872C2 (ru) |
| SG (1) | SG184127A1 (ru) |
| WO (1) | WO2011115684A2 (ru) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010059253A2 (en) | 2008-11-24 | 2010-05-27 | Massachusets Institute Of Technology | Methods and compositions for localized agent delivery |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US20100323018A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Branched DNA/RNA monomers and uses thereof |
| US20100324124A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Compositions and methods relating to DNA-based particles |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| SG184127A1 (en) | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
| SG2014010409A (en) | 2011-05-10 | 2014-05-29 | Penn State Res Found | Ceramide anionic liposome compositions |
| AU2013216861B2 (en) * | 2012-02-10 | 2017-05-18 | Tlc Biopharmaceuticals, Inc | Pharmaceutical compositions to reduce complications of ocular steroid |
| WO2014026284A1 (en) * | 2012-08-14 | 2014-02-20 | Froese Aaron | Internal structured self assembling liposomes |
| WO2014070659A1 (en) * | 2012-10-29 | 2014-05-08 | The Regents Of The University Of California | Composition of viral vectors in lecithin liposomes, preparation method and treatment methods |
| WO2014074952A1 (en) | 2012-11-09 | 2014-05-15 | Massachusetts Institute Of Technology | Methods and compositions for localized delivery of agents to hiv-infected cells and tissues |
| JP2016513712A (ja) | 2013-03-14 | 2016-05-16 | ジェローム, ジェイ. シェンターク, | カイロミクロンへの分子の取り込みのためのコレストソーム小胞 |
| EP3650038A1 (en) | 2013-06-19 | 2020-05-13 | Massachusetts Institute of Technology | In vivo targeting of cells with ligand-conjugated particles |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| CN103565746B (zh) * | 2013-11-20 | 2015-05-20 | 河南牧翔动物药业有限公司 | 一种安普霉素脂质体及其制备方法 |
| WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US20160228573A1 (en) * | 2014-08-14 | 2016-08-11 | L.E.A.F. Holdings Group Llc | Liposome encapsulated affinity drug |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| AU2015314763A1 (en) * | 2014-09-11 | 2017-04-06 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions and methods of use |
| WO2016057427A1 (en) | 2014-10-06 | 2016-04-14 | Lawrence Livermore National Security, Llc | Nanotube trans-membrane channels mimicking biological porins |
| CA2971408C (en) | 2014-12-17 | 2019-12-10 | Sri International | Targeted stealth liposomes loaded with an immunogenic human leukocyte antigen class i restricted peptide |
| BR112017013623A2 (pt) * | 2014-12-23 | 2018-03-13 | Council Of Scientific And Industrial Research | formulação de vacina de dna em veículo de lipossoma catiônico útil para maximizar a potência da vacina contra leishmaniose |
| WO2016115480A1 (en) * | 2015-01-16 | 2016-07-21 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
| US10307491B2 (en) * | 2015-01-30 | 2019-06-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CA2977397A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| AU2016238290B9 (en) | 2015-03-25 | 2019-06-13 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| AU2016305087B2 (en) | 2015-08-12 | 2022-01-20 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| EP3156046A1 (en) * | 2015-10-16 | 2017-04-19 | Centre National De La Recherche Scientifique (Cnrs) | Amphiphilic molecules layers |
| WO2017091561A1 (en) | 2015-11-25 | 2017-06-01 | Corning Incorporated | Systems and methods for expressing proteins |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US20190142921A1 (en) * | 2016-05-17 | 2019-05-16 | Cornell University | Compositions and methods for the expression of eukaryotic oligosaccharides on bacterial outer membrane vesicles |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES |
| KR101881219B1 (ko) * | 2016-07-22 | 2018-07-23 | 성균관대학교산학협력단 | 영상화용 발광 입자체, 이를 이용한 세포 영상화 방법, 및 이의 제조방법 |
| KR102584446B1 (ko) | 2016-08-12 | 2023-10-04 | 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. | 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도 |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| KR102069670B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
| JP6482604B2 (ja) * | 2017-06-22 | 2019-03-13 | 教裕 南郷 | 外皮内溶解型ニードル及びニードル装置 |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| MA50532A (fr) | 2017-11-03 | 2020-09-09 | Univ Virginia Patent Foundation | Compositions et méthodes pour le traitement de cancers |
| WO2019143969A1 (en) * | 2018-01-18 | 2019-07-25 | Claudio Maldonado | Treating microvascular dysfunction |
| WO2019157133A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| US12246018B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| WO2019157146A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| JP7514533B2 (ja) | 2018-02-07 | 2024-07-11 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| US12048767B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| JP7442822B2 (ja) | 2018-02-14 | 2024-03-05 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | γポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| US12290518B2 (en) | 2018-02-14 | 2025-05-06 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP4582440A3 (en) * | 2018-12-21 | 2025-10-08 | The Regents of the University of California | Il-10-containing vaccines and uses thereof |
| US11154502B2 (en) | 2019-01-24 | 2021-10-26 | CannaClear Inc. | Lecithin vesicles for oral delivery |
| US12201724B2 (en) | 2019-01-24 | 2025-01-21 | CannaClear Inc. | Lecithin vesicles for oral delivery |
| US12324800B2 (en) | 2019-01-24 | 2025-06-10 | CannaClear Inc. | Lecithin vesicles |
| US12702719B2 (en) | 2019-03-06 | 2026-08-11 | Northwestern University | Hairpin-like oligonucleotide-conjugated spherical nucleic acid |
| CA3143533A1 (en) * | 2019-08-01 | 2021-02-04 | Madhavan Nallani | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome |
| WO2021053163A1 (en) | 2019-09-19 | 2021-03-25 | Danmarks Tekniske Universitet | Immune stimulating micelle composition |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| WO2021119552A1 (en) | 2019-12-13 | 2021-06-17 | Lawrence Livermore National Security, Llc | Nanotube-vesicle compositions and uses thereof |
| CN111671727B (zh) * | 2020-05-22 | 2022-03-29 | 哈尔滨工业大学 | 一种基于疏水相互作用构筑蛋白质/磷脂/胆固醇多元杂合微尺度囊泡的方法 |
| CN112336855B (zh) * | 2020-07-28 | 2021-06-25 | 江苏飞阳益科生物科技有限公司 | 一种阳离子脂质体禽流感疫苗及其制备方法 |
| CN111759811B (zh) * | 2020-08-06 | 2022-08-02 | 淄博职业学院 | 无刺激性克拉霉素冻干粉及其制备方法 |
| EP4196095A4 (en) * | 2020-08-13 | 2024-10-16 | The Regents Of The University Of Colorado, A Body Corporate | Phospholipid bilayers catalytically promote protein refolding, inhibit and reverse protein aggregate formation, and methods of treating neurodegenerative diseases using the same |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| TW202237069A (zh) * | 2020-12-14 | 2022-10-01 | 美商納米科技製藥公司 | 用於遞送具經改良的治療指數之抗癌藥劑之組合物與方法 |
| EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
| WO2023022384A1 (ko) * | 2021-08-17 | 2023-02-23 | 한국과학기술원 | 면역 유도용 다층 소포체, 이를 포함하는 면역 유도용 약학 조성물 및 면역 유도용 다층 소포체의 제조방법 |
| EP4408480A4 (en) * | 2021-09-30 | 2025-07-23 | Univ Michigan Regents | COMPOSITIONS AND METHODS FOR METAL-CONTAINING FORMULATIONS CAPABLE OF MODULATING AN IMMUNE RESPONSE |
| CN116203109B (zh) * | 2021-12-01 | 2026-08-04 | 中国科学院大连化学物理研究所 | 一种用于递送交联剂至细胞内线粒体的纳米脂质体类转运载体及其制备和应用 |
| WO2024010886A2 (en) * | 2022-07-07 | 2024-01-11 | Nanostar Pharmaceuticals Ltd. | Multilamellar vesicle drug formulation |
| US20240108545A1 (en) | 2022-10-03 | 2024-04-04 | West Pharmaceutical Services, Inc. | Methods and adapters for mixing pharmaceutical complexes |
| US12673026B2 (en) * | 2023-06-06 | 2026-07-07 | SpecNova LLC | Liposomal compositions and methods of use thereof for improved stability, bioavailability and sustained release |
| CN119120376A (zh) * | 2023-07-10 | 2024-12-13 | 浙江大学医学院附属第一医院 | 一种用于清除致病抗体的嵌合基因工程化纳米囊泡及其制备方法、应用 |
| EP4766394A2 (en) * | 2023-08-21 | 2026-07-01 | The Board of Trustees of the Leland Stanford Junior University | UNIVERSAL VACCINATION STRATEGY TO PROVIDE PROTECTION AGAINST VARIOUS PATHOGENS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143305A (en) * | 1973-05-07 | 2000-11-07 | The Ohio State University | Antigenically modified polypeptides composition |
| JPS60231609A (ja) | 1984-04-28 | 1985-11-18 | Terumo Corp | リポソ−ム製剤 |
| US5460831A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| US5753261A (en) * | 1993-02-12 | 1998-05-19 | Access Pharmaceuticals, Inc. | Lipid-coated condensed-phase microparticle composition |
| US5532133A (en) * | 1993-06-02 | 1996-07-02 | New York University | Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays |
| US5534259A (en) * | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5464629A (en) * | 1993-11-16 | 1995-11-07 | Georgetown University | Method of forming hydrogel particles having a controlled size using liposomes |
| AU713040B2 (en) * | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| IN190388B (ru) * | 1997-10-01 | 2003-07-26 | Biomira Usa Inc | |
| US6187335B1 (en) * | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| DE19852928C1 (de) | 1998-11-17 | 2000-08-03 | Steffen Panzner | Strukturen in Form von Hohlkugeln |
| ATE328582T1 (de) * | 1999-04-23 | 2006-06-15 | Mitsubishi Chem Corp | Antikörper und polyalkylenglycol gebundenes liposom |
| CN1406125A (zh) * | 2000-02-25 | 2003-03-26 | 健康研究股份有限公司 | 分子材料透皮或皮内输递的方法 |
| US20030235619A1 (en) * | 2001-12-21 | 2003-12-25 | Christine Allen | Polymer-lipid delivery vehicles |
| AU2003217950A1 (en) | 2002-03-05 | 2003-09-22 | Cleveland State University | Agglomerated particles for aerosol drug delivery |
| JP5014573B2 (ja) * | 2002-05-09 | 2012-08-29 | オンコサイレオン インコーポレーテッド | 脂質aおよび他の炭水化物リガンド類似体 |
| US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| US20050042298A1 (en) * | 2003-08-20 | 2005-02-24 | Pardridge William M. | Immunonanoparticles |
| EP1550458A1 (en) * | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| DE102004054536A1 (de) | 2004-11-06 | 2006-05-11 | Capsulution Nanoscience Ag | Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel |
| US7790186B2 (en) * | 2005-01-18 | 2010-09-07 | The United States Of America As Represented By The Secretary Of The Army | Plasmodium vivax hybrid circumsporozoite protein and vaccine |
| WO2006119121A2 (en) * | 2005-04-29 | 2006-11-09 | University Of Louisville Research Foundation, Inc. | Cell-surface decoration with active agents |
| US8246995B2 (en) * | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| WO2007022152A2 (en) * | 2005-08-15 | 2007-02-22 | The Research Foundation Of State University Of New York | Lipid nano particulates containing antigens as cancer vaccines |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| CA2601803A1 (en) * | 2006-01-13 | 2007-07-19 | Riken | Preventive or therapeutic agent and method for immune disease |
| CA2600220C (en) | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
| CA2705797A1 (en) * | 2007-11-14 | 2009-05-22 | The Regents Of The University Of California | Sterol-modified amphiphilic lipids |
| WO2010059253A2 (en) | 2008-11-24 | 2010-05-27 | Massachusets Institute Of Technology | Methods and compositions for localized agent delivery |
| CA2754896C (en) * | 2009-03-09 | 2017-11-28 | Molecular Express, Inc. | Methods and compositions for liposomal formulation of antigens and uses thereof |
| US20100324124A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Compositions and methods relating to DNA-based particles |
| US20100323018A1 (en) * | 2009-06-17 | 2010-12-23 | Massachusetts Institute Of Technology | Branched DNA/RNA monomers and uses thereof |
| US20110229556A1 (en) * | 2010-03-19 | 2011-09-22 | Massachusetts Institute Of Technology | Lipid-coated polymer particles for immune stimulation |
| SG184127A1 (en) * | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
| US9149432B2 (en) * | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
-
2011
- 2011-03-19 SG SG2012069035A patent/SG184127A1/en unknown
- 2011-03-19 US US13/052,067 patent/US8747869B2/en not_active Expired - Fee Related
- 2011-03-19 KR KR1020127027175A patent/KR101783068B1/ko not_active Expired - Fee Related
- 2011-03-19 WO PCT/US2011/000502 patent/WO2011115684A2/en not_active Ceased
- 2011-03-19 MX MX2012010810A patent/MX2012010810A/es active IP Right Grant
- 2011-03-19 AU AU2011227686A patent/AU2011227686B2/en not_active Ceased
- 2011-03-19 JP JP2013501243A patent/JP5686886B2/ja not_active Expired - Fee Related
- 2011-03-19 CA CA2793604A patent/CA2793604C/en not_active Expired - Fee Related
- 2011-03-19 RU RU2012144392/15A patent/RU2595872C2/ru not_active IP Right Cessation
- 2011-03-19 CN CN201180023709.8A patent/CN102917690B/zh not_active Expired - Fee Related
- 2011-03-19 BR BR112012023501A patent/BR112012023501A2/pt not_active Application Discontinuation
- 2011-03-19 EP EP11716090.3A patent/EP2547327B1/en not_active Not-in-force
-
2012
- 2012-09-19 IL IL221989A patent/IL221989A/en not_active IP Right Cessation
-
2014
- 2014-04-30 US US14/265,924 patent/US8951542B2/en active Active
- 2014-12-23 US US14/581,004 patent/US9339462B2/en active Active
-
2016
- 2016-04-13 US US15/097,607 patent/US9616020B2/en active Active
-
2017
- 2017-03-08 US US15/452,992 patent/US9907753B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL221989A (en) | 2017-02-28 |
| BR112012023501A2 (pt) | 2016-05-31 |
| WO2011115684A3 (en) | 2012-08-09 |
| US20150272884A1 (en) | 2015-10-01 |
| US20140271827A1 (en) | 2014-09-18 |
| US20110229529A1 (en) | 2011-09-22 |
| CA2793604A1 (en) | 2011-09-22 |
| KR20130016301A (ko) | 2013-02-14 |
| US9339462B2 (en) | 2016-05-17 |
| US8747869B2 (en) | 2014-06-10 |
| US9616020B2 (en) | 2017-04-11 |
| SG184127A1 (en) | 2012-10-30 |
| CN102917690A (zh) | 2013-02-06 |
| WO2011115684A2 (en) | 2011-09-22 |
| JP2013522362A (ja) | 2013-06-13 |
| US8951542B2 (en) | 2015-02-10 |
| CA2793604C (en) | 2015-10-06 |
| MX2012010810A (es) | 2013-02-07 |
| KR101783068B1 (ko) | 2017-09-28 |
| EP2547327B1 (en) | 2018-09-05 |
| AU2011227686B2 (en) | 2014-12-04 |
| US20160303046A1 (en) | 2016-10-20 |
| US9907753B2 (en) | 2018-03-06 |
| RU2595872C2 (ru) | 2016-08-27 |
| CN102917690B (zh) | 2016-08-24 |
| AU2011227686A1 (en) | 2012-10-11 |
| US20170266114A1 (en) | 2017-09-21 |
| JP5686886B2 (ja) | 2015-03-18 |
| EP2547327A2 (en) | 2013-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123677A1 (es) | Preparación y almacenamiento de formulaciones de rna liposomal adecuadas para terapia | |
| MX2025002671A (es) | Lipidos para uso en formulaciones de nanoparticulas de lipidos | |
| KR102204725B1 (ko) | 관절의 통증 및 감소된 활동성의 치료에 사용하기 위한 소포성 제형 | |
| ES3013745T3 (en) | Methods and compositions for modulating the immune system with arginase i | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| JP2004525138A (ja) | 治療剤の改良された細胞内送達のためのリポソーム組成物 | |
| MX2022013984A (es) | Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). | |
| CA2751412A1 (en) | Methods of reducing the proliferation and viability of microbial agents | |
| CN115335084A (zh) | 包含聚肌氨酸的rna颗粒 | |
| AR069979A1 (es) | Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados | |
| WO2011022707A1 (en) | Vesicular formulations | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| FI4417216T3 (fi) | Neisseria meningitidis rlp2086 -antigeenien stabiilit koostumukset | |
| BRPI1010861A2 (en) | methods for treating pain, inflammation or osteoarthritis, pharmaceutical package and formulation | |
| CN106132970A (zh) | 硼酸酯和其药物制剂 | |
| CN119156205A (zh) | 用于施用rna的基于脂质的制剂 | |
| ES2329374T3 (es) | Formulaciones farmaceuticas que utilizan esfingolipidos de cadena corta y usos de las mismas. | |
| WO2024211865A3 (en) | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery | |
| AU2014298426B2 (en) | Vesicles | |
| PE20130064A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| CN104349782A (zh) | 囊泡制剂 | |
| ES2001099A6 (es) | Procedimiento para la preparacion de una composicion farmaceutica a base de fosfolipidos. | |
| US20150125407A1 (en) | Vesicular Formulations, Uses and Methods | |
| WO2013171132A1 (en) | Vesicular formulations, kits and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190320 |